[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547234":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":24,"locations":33,"responsibleParty":52,"collaborators":10,"id":54,"slug":55,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":10,"studyType":67,"phases":10,"briefSummary":68,"conditions":69,"keywords":71,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"Guangxi Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Conversion or Neoadjuvant Therapy",null,"Patients with hepatocellular carcinoma received conversion or neoadjuvant therapy.",[13],"Drug: Conversion or neoadjuvant therapy.",[15],{"type":16,"name":17,"description":11,"armGroupLabels":18,"otherNames":10},"DRUG","Conversion or neoadjuvant therapy.",[9],[20],{"name":21,"affiliation":22,"role":23},"Jian-Hong Zhong, Ph.D","Guangxi Medical University Cancer Hospital","PRINCIPAL_INVESTIGATOR",[25,30],{"name":21,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","+86 771 5301253","+86","zhongjianhong66@163.com",{"name":31,"role":26,"phone":27,"phoneExt":28,"email":32},"Liang Ma, MD","malianggxyd@163.com",[34],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":38,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Jian-Hong Zhong","RECRUITING","Nanning","China","530021","CN",{"type":42,"coordinates":43},"Point",[44,45],108.31667,22.81667,{"lat":45,"lon":44},[48,51],{"name":49,"role":26,"phone":50,"phoneExt":28,"email":29},"Jian-Hong Zhong, PhD","0771 5301253",{"name":31,"role":26,"phone":50,"phoneExt":28,"email":32},{"type":23,"investigatorFullName":35,"investigatorTitle":53,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"Principal Investigator","100547234","conversion-or-neoadjuvant-therapy-in-hepatocellular-carcinoma-100547234",false,"NCT06405321","Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma","Conversion or Neoadjuvant Therapy in Hepatocellular Carcinoma: A Multicenter Retrospective Study in Guangxi, China (GUIDANCE)","Inclusion Criteria:\n\n* Histologically or clinically confirmed diagnosis of HCC.\n* Patients who received conversion or neoadjuvant therapy as initial treatment, including hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), tyrosine kinase inhibitors (TKIs), immune checkpoint inhibitors (ICIs), or radiotherapy.\n* Eastern Cooperative Oncology Group performance status (ECOG-PS) of 0 or 1.\n* With Child-Pugh 5\\~7 scores.\n\nExclusion Criteria:\n\n* Concurrent with other malignancies within 5 years.\n* Incomplete medical data.\n* Follow-up time less than 3 months.","ALL","18 Years","75 Years",{"count":65,"type":66},2000,"ESTIMATED","OBSERVATIONAL","This multicenter retrospective study which included patients with hepatocellular carcinoma (HCC) who received conversion or neoadjuvant therapy to explore the best treatment options and the best benefit group.",[70],"Hepatocellular Carcinoma",[72,73],"conversion therapy","neoadjuvant therapy","2026-01-13",{"date":76,"type":77},"2026-01-14","ACTUAL",{"date":79,"type":77},"2019-01-01",{"date":81,"type":66},"2026-12-31",{"name":5,"class":6},1]